Get started
Author

S. Bar‐Yehuda

Observed names: S Bar-Yehuda, S. Bar-Yehuda
OpenAlex ID: A5111367087
Adenosine Receptors and Cancer
2009 · P. Fishman, S. Bar-Yehuda, et al. · Handbook of experimental pharmacology · 148
Immune dysregulation to Ethiopian immigrants in Israel: relevance to helminth infections?
1996 · Z Bentwich, Z Weisman, et al. · Clinical & Experimental Immunology · 141
Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment
2009 · S. Bar‐Yehuda, L. Rath‐Wolfson, et al. · Arthritis & Rheumatism · 126
The anti-inflammatory target A3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn’s disease
2009 · A. Ochaion, S. Bar-Yehuda, et al. · Cellular Immunology · 119
Adenosine acts as an inhibitor of lymphoma cell growth
2000 · P. Fishman, S. Bar-Yehuda, et al. · European Journal of Cancer · 93
Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101
2003 · G Ohana, S Bar-Yehuda, et al. · British Journal of Cancer · 90
PDF
CF102 an A3 adenosine receptor agonist mediates anti‐tumor and anti‐inflammatory effects in the liver
2010 · S. Cohen, S.M. Stemmer, et al. · Journal of Cellular Physiology · 78
Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth.
1998 · P Fishman, S Bar-Yehuda, et al. · PubMed · 71
The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-κB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats
2008 · A. Ochaion, S. Bar-Yehuda, et al. · Biochemical Pharmacology · 70
Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men
2004 · A.-R. van Troostenburg, E.V. Clark, et al. · International Journal of Clinical Pharmacology and Therapeutics · 64
IB-MECA, an A3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis.
2006 · L Rath-Wolfson, S Bar-Yehuda, et al. · PubMed · 61
A3 Adenosine Receptor: Pharmacology and Role in Disease
2009 · P.A. Borea, S. Gessi, et al. · Handbook of experimental pharmacology · 59
The Anti-Cancer Effect of A3 Adenosine Receptor Agonists: A Novel, Targeted Therapy
2007 · P. Fishman, K.A. Jacobson, et al. · Immunology Endocrine & Metabolic Agents - Medicinal Chemistry · 21
High prevalence of HIV-specific immunity in seronegative Ethiopian immigrants in Israel.
1997 · S Bar-Yehuda, Z Weisman, et al. · PubMed · 7
1411 Cf102 for the Treatment of Hepatocellular Carcinoma: a Phase I/ii, Open-label, Dose-escalation Study
2012 · S.M. Stemmer, O. Benjaminov, et al. · Journal of Hepatology · 4
Mononuclear cells release low molecular weight factors with anti-cancer activity: A lower level of production by cells of cancer patients.
1998 · D Cohen-Aloro, O Merimsky, et al. · International Journal of Oncology · 1
Pending problem of "silent" human immunodeficiency virus infection.
1995 · Z Bentwich, S Bar-Yehuda, et al. · PubMed · 1
CF101 for the Treatment of Autoimmune Inflammatory Diseases: Data from Phase 2 Clinical Trials in Patients with Rheumatoid Arthritis, Psoriasis and Dry Eye Syndrome
2010 · Paul Fishman, S. Bar‐Yehuda, et al.
Works count: 18
Citation count: 1,154
H-index: 13
I10-index: 13
Year
Topic
Type